

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4804697

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MADRIGAL PHARMACEUTICALS, INC.	10/20/2017
RECEIVING PARTY DATA	
Name:	PRCL RESEARCH INC.
Street Address:	1255 UNIVERSITY
Internal Address:	#1610
City:	MONTREAL
State/Country:	CANADA
Postal Code:	H3B 3X3
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	8518950
Patent Number:	9090570
Patent Number:	9493427
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	514-847-4747
Email:	sheri.vandray@nortonrosefulbright.com
Correspondent Name:	NORTON ROSE FULBRIGHT CANADA LLP
Address Line 1:	1 PLACE VILLE MARIE
Address Line 2:	SUITE 2500
Address Line 4:	MONTREAL, CANADA H3B 1R1
ATTORNEY DOCKET NUMBER:	55941658-GEN-MTL
NAME OF SUBMITTER:	PATRICE PREVILLO
SIGNATURE:	/PATRICE PREVILLO/
DATE SIGNED:	02/01/2018
Total Attachments: 3	
source=UniversalAssignmentMadrigaltoPRCL1#page1.tif	
source=UniversalAssignmentMadrigaltoPRCL1#page2.tif	

Our Reference: 55941658-1**

UNIVERSAL ASSIGNMENT OF INVENTION

WHEREAS,

Name: MADRIGAL PHARMACEUTICALS, INC.

Address: Four Tower Bridge, 200 Barr Harbor Drive, Suite 400, West Conshohocken PA 19428, United States

(hereinafter referred to as the "Assignor"), has owned one or more invention(s) relating to and entitled

COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES

set forth and described in the attached Appendix (1)

(herein after referred to as the "Invention");

AND WHEREAS,

Name: PRCL RESEARCH INC.

Address: 1255 University #1610 Montréal QC H3B 3X3, Canada

(hereinafter referred to as the "Assignee")

desires to have the entire right, title, interest, property and benefit in and for Canada, the United States, and all other countries and jurisdictions in the world, in and to the Invention;

NOW THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor agrees to and does hereby:

confirm to have sold, assigned, transferred, and set over to the Assignee, and, to any extent to have not already sold, assigned, transferred or set over to Assignee, does hereby sell, assign, transfer and set over to the Assignee, and to the Assignee's successors, assigns, nominees or other legal representatives, its entire right, title, interest, property and benefit including any right to sue for past infringements in and for Canada, the United States, and all other countries and jurisdictions in the world, in and to the Invention, any and all applications filed therefore, including any and all corresponding applications whether in the form of divisions, continuations, re-examinations, re-issues and extensions thereof, any and all patents that may issue, be granted or result therefrom for the Invention, and any and all rights of priority resulting from the filing of any of the above-identified applications and any previously filed applications in respect of the Invention under international conventions, treaties or otherwise, the same to be held and enjoyed fully and exclusively;

do all lawful acts and to execute and deliver, without further consideration other than expenses reasonably incurred, all further documents as may reasonably be required by the Assignee, or by its successors, assigns, nominees, or other legal representatives, to obtain said Patents in Canada and all other countries and jurisdictions for the Invention and vest or secure the same in the Assignee, and in the Assignee's successors, assigns, nominees or other legal representatives; and

grant to said Assignee, its successors, assigns, nominees or other legal representatives, including its patent agents and attorneys, the power to insert on this assignment any further information which may be necessary or desirable in order to place this document in compliance for recordation.

THIS ASSIGNMENT may be executed in counterparts, all of which shall be considered one and the same agreement.

Date: 2017/10/20
(YYYY/MM/DD)

Assignor: X Marc R. Schneebaum
For: MADRIGAL PHARMACEUTICALS, INC.
Name: Marc R. Schneebaum
Title: Senior Vice President and Chief Financial Officer

2017 (considered) PA
Place of Execution

Witness: X Frank Ambrogio
Name: FRANK AMBROGIO

Date: 25 Oct 2017
(YYYY/MM/DD)

Assignor: X Caroline Fortier
For: PRCL RESEARCH INC.
Name: Caroline Fortier
Title: Chief Executive Officer

Montreal, QC
Place of Execution

Witness: X Stephanie Larosa
Name: STEPHANIE LAROSA

Declaration of Witness

Each witness hereby declares that he/she was personally present and did see the inventor for which he/she is witnessing duly sign and execute the foregoing assignment on the day and year set forth above, the inventor being personally known to the witness as the person named above.

APPENDIX (1)

Title: COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES

NRFC Ref.	Country	Official No.	Case Status
55941658-1AU	Australia	2006208045	Granted
55941658-1BE	Belgium	1848435	Granted
55941658-1CA	Canada	2595855	Granted
55941658-1CN	China	101163478	Granted
55941658-1DE	Germany	1848435	Granted
55941658-1EP	Europe	1848435	Granted
55941658-1ES	Spain	1848435	Granted
55941658-1FR	France	1848435	Granted
55941658-1GB	United Kingdom	1848435	Granted
55941658-1HK	Hong Kong	HK11110240	Granted
55941658-1IL	Israel	184756	Granted
55941658-1IT	Italy	1848435	Granted
55941658-1JP	Japan	5307402	Granted
55941658-1KR	Republic of Korea	10-1436161	Granted
55941658-1MX	Mexico	319435	Granted
55941658-1NL	Netherlands	1848435	Granted
55941658-1NZ	New Zealand	556732	Granted
55941658-1NZ-1	New Zealand	590359	Granted
55941658-1PL	Poland	1848435	Granted
55941658-1RO	Romania	1848435	Granted
55941658-1TW	Taiwan	1422376	Granted
55941658-1US	United States	8518950	Granted
55941658-1US-1	United States	9090570	Granted